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PURPOSE. To investigate the role of ERK1/2 and RhoA/ROCK
intracellular pathways in the modification of corneal re-epithe-
lialization when stimulated by the diadenosine polyphosphates
Ap4A and Ap3A.
METHODS. In wounded confluent SIRC (Statens Seruminstitut rab-
bit cornea) cell monolayers and in the presence or absence of
Ap4A or Ap3A 100 M, a battery of P2 receptor antagonists
and inhibitors of tyrosin kinases, MAPK, and cytoskeleton path-
ways (AG1478 100 M, U0126 100 M, Y27632 100 nM, and
()-blebbistatin 10 M; n  8 each) were assayed. Also, the
activation of ERK1/2 and ROCK-I was examined by Western blot
assay after treatment with Ap4A and Ap3A (100 M), with or
without suramin, RB-2, U0126, and Y27632. The intracellular
distribution of pERK and ROCK-I was examined in the presence
of Ap4A or Ap3A (100 M) with U0126 and Y27632 (100 nM).
RESULTS. In the presence of Ap4A, U0126, Y27632, AG1478,
and ()-blebbistatin, reduced the migration rate compared to
the effect of Ap4A alone (P 0.0001, P 0.001, P 0.01, and
P  0.1 versus Ap4A, respectively). In the presence of Ap3A
100 M, U0126 and Y27632 accelerated the migration rate
when compared with the effect of Ap3A alone, whereas
AG1478 and ()-blebbistatin (P 0.0001 versus Ap3A) slowed
the migration rate. Western blot assays demonstrated that both
dinucleotides activated the ERK1/2 pathway but only Ap4A
activated the ROCK-I pathway. The intracellular distribution of
pERK1/2 and ROCK-I reflected cross-talk between these two
pathways.
CONCLUSIONS. The activation of the Ap4A/P2Y2 receptor, accel-
erates corneal epithelial cell migration during wound healing
with the activation of MAPK and cytoskeleton pathways,
whereas activation of the Ap3A/P2Y6 receptor signals only the
MAPK pathway. (Invest Ophthalmol Vis Sci. 2008;49:
4982–4992) DOI:10.1167/iovs.07-1583
Dinucleoside polyphosphates (NpnN) are compounds thathave interesting physiological properties in various tissues
similar to those of mononucleotides.1–3 The most commonly
studied dinucleotides are diadenosine polyphosphates (ApnA,
where n  3 to 7). These compounds mediate a variety of
functions, such as inhibition of adenosine kinase and adenylate
kinase,4 stimulation of nitric oxide release from endothelial
cells,5 inhibition of platelet aggregation,6 and facilitation of
neurotransmitter release from synaptic terminals in the central
nervous system.7
As happens with nucleotides, these compounds exert their
functions by binding to membrane receptors termed P2 puri-
noceptors,8 as well as to their own dinucleotide receptors.7 P2
receptors are organized into two families: ionotropic P2X re-
ceptors and metabotropic P2Y receptors. P2X receptors are
formed by two or three subunits that construct an active
receptor,9 which forms an ATP-gated ion channel that medi-
ates rapid and selective permeability to cations.10 Seven P2X
receptor subunits (P2X1 to P2X7) have been cloned so far.
9,11
This subtype of P2 receptors is involved in processes in which
the cell is excited by nucleotides, similar to the excitation in
neurons.12
P2Y receptors are seven-transmembrane-domain proteins
coupled to G proteins that trigger different signal transduction
pathways: phospholipase C, adenylate cyclase, or MAPK.13–15
Eight different P2Y receptors have been cloned: P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14.
16 Although in
general all the receptors are widely distributed, the last four are
particularly important in processes such as the maintenance of
the vascular tone and platelet aggregation.17,18
The presence of diadenosine polyphosphates in ocular flu-
ids and their effect in ocular tissues has already been demon-
strated. For instance, diadenosine polyphosphates have been
identified in tear and aqueous humor, together with other
nucleotides.19 They also exert several actions in the eye by
stimulating P2 receptors. These actions include the reduction
of intraocular pressure (IOP) and modification of the activity of
both neuronal and glial retinal cells.19
On the ocular surface, the presence of diadenosine triphos-
phate (Ap3A), diadenosine tetraphosphate (Ap4A), and diaden-
osine pentaphosphate (Ap5A) have been described.
20,21 They
have been found to be involved in modifying the rate of
corneal re-epithelialization in New Zealand White rabbits, both
in vivo22 and in vitro.23 We have demonstrated that Ap4A
produces acceleration in the rate of corneal re-epithelialization
by stimulating P2Y2 receptors, and Ap3A and Ap5A exert the
opposite effect, delaying corneal re-epithelialization by binding
to the P2Y6 receptor.
23
Several groups24–26 have linked corneal wound healing
with the members of the mitogen-activated protein kinase
(MAPK) and the RhoA/ROCK family. The MAPK cascade is one
of the most ubiquitous signal transduction systems and is
activated in response to many extracellular stimuli, such as
cellular stress, cell death, and injury.27 The Rho family of small
GTPases has been implicated in the formation of actin stress
fibers and focal adhesions.28,29 The effects of Rho appear to
be regulated by the activation of Rho-associated kinases
(ROCK).30 Two isoforms of ROCK (ROCKI/ROK and
From Departamentos de 1Bioquímica y Biología Molecular IV y de
2O´ptica II, E.U. O´ptica, Universidad Complutense de Madrid, Madrid,
Spain.
Supported by Grants NEUROTRANS-CM Ref. 0253-2006 and
PR1/07 to 14890 from Universidad Complutense de Madrid. AM is a
fellowship holder from the Universidad Complutense de Madrid.
Submitted for publication December 11, 2007; revised June 9,
2008; accepted September 17, 2008.
Disclosure: A. Mediero, None; A. Guzma´n-Aranguez, None; A.
Crooke, None; A. Peral, None; J. Pintor, None
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked “advertise-
ment” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Jesu´s Pintor, Departamento Bioquímica y
Biología Molecular IV, Escuela Universitaria de O´ptica, Universidad
Complutense de Madrid, c/Arcos de Jalo´n s/n, 28037 Madrid, Spain;
jpintor@vet.ucm.es.
Investigative Ophthalmology & Visual Science, November 2008, Vol. 49, No. 11
4982 Copyright © Association for Research in Vision and Ophthalmology
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/932946/ on 10/18/2016
ROCKII/ROK) have been identified.31 In addition, there is
evidence that P2Y receptors may play a role in signal transduc-
tion with the activation of both the MAPK32–34 and RhoA/
ROCK cascades.35
In the present work, we studied the role of ERK1/2 and
RhoA/ROCK pathways in the modification of the re-epithelial-
ization rate triggered by the diadenosine polyphosphates Ap4A
and Ap3A in an established corneal epithelial cell line: SIRC
(Statens Seruminstitut rabbit cornea).
METHODS
Reagents
The dinucleotides Ap4A and Ap3A were purchased from Sigma-Aldrich
(St. Louis, MO). Suramin was from Tocris (Bristol, UK). Several antag-
onists and inhibitors (reactive blue 2 [RB-2]), U0126, Y27632, and
()-blebbistatin) were from Sigma-Aldrich, and AG1478 was from
Calbiochem (San Diego, CA). Minimum essential medium (MEM) with
Earle’s salts, L-glutamine, and nonessential amino acids and fetal bovine
serum were from Invitrogen (Paisley, UK). Primary antibodies against
pERK1/2, ERK-2, ROCK-I, MLC2, goat anti-mouse IgG-HRP secondary
antibody, and goat anti-mouse IgG-TRICT secondary antibody were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Primary
antibody against pMLC2 was purchased from Cell Signaling (Izasa S.A.,
Barcelona, Spain). Bradford reagent and acrylamide-bisacrylamide were
from Bio-Rad (Hercules CA; Alcobendas, Madrid, Spain). Nitrocellulose
membrane and a chemiluminescence detection system (Hyperfilm
ECL) were from GE Healthcare (Barcelona, Spain). Phenylmethylsulfo-
nyl fluoride (PMSF), sodium fluoride (NaF), sodium orthovanadate
(Na3VO4), pepstatin A, leupeptin, aprotinin, and NP-40 were from
Sigma-Aldrich. The SIRC cells were obtained from American Type
Culture Collection (ATCC; LGC Promochem SL, Barcelona, Spain).
Cell Culture
All animals were treated in accordance with the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research and in accor-
dance with the European Communities Council Directive (89/609/
EEC). Primary corneal epithelial cells were obtained from healthy eyes
of adult New Zealand White rabbits euthanized with pentothal sodium.
Cell culture was performed according to the protocol previously de-
scribed.17,23 Briefly, the eyes were enucleated, and the globes were
placed in Hanks’ balanced salt solution (HBSS) while corneal dissection
was performed under a dissecting microscope. The cornea was re-
moved along the limbus and cut into pieces. Incubation of the corneas
in 1.0 U Dispase II (Roche Molecular Biochemicals, Indianapolis, IN)
was performed for 1 hour at 37°C in 5% CO2 and 95% humidity. The
epithelium was peeled from the stroma and placed in 0.05% trypsin 0.5
M EDTA for 20 minutes at 37°C. The specimen was collected in a tube
containing 10 mL Dulbecco’s modified Eagle’s medium (DMEM; In-
vitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin
(both from Invitrogen) and centrifuged twice at 1100 rpm for 6
minutes at 4°C. Finally, the cells were resuspended in DMEM supple-
mented with 10% FBS and 1% penicillin-streptomycin and cultured in
six multiwell plates until confluence. They were kept in a CO2 incu-
bator at 37°C 5% CO2 and 95% humidity until confluence.
Cells from an established rabbit corneal epithelial cell line (SIRC)
were maintained in minimum essential medium (MEM) with Earle’s
salts, L-glutamine, and nonessential amino acids supplemented with
10% activated FBS and incubated at 37°C in 5% CO2 and 95% humidity
until confluence.
Migration Assays
To determine the correlation between primary corneal epithelial cells
and the SIRC cell line, we performed a migration assay on SIRC cells.
Ap4A or Ap3A (100 M) was added to wounded monolayers according
to a protocol described for primary cultures.23 Briefly, SIRC confluent
monolayers were wounded by scraping the cell monolayer with a
pipette tip.23 The initial wound size and shape were intended (60,000–
80,000 m2) to take into account the variations in wound closure due
to size, so that healing shared the same mechanistic features as previ-
ously indicated in other investigations.36 Wound area measurements
(for each treatment) were collected from eight different wells and
averaged (mean  SEM). These eight experiments were performed in
four independent cell cultures. The cells were challenged with the
dinucleotide dose for 2 minutes in Locke medium, to avoid interfer-
ence by components of media such as DMEM.37 After incubation, the
cells were washed and fresh MEM was added. A control experiment
was performed by challenging the wounded monolayers with Locke
medium along (n 8). The dinucleotide dose was added to the wound
at time 0 and 6 hours, as previously described for rabbits.22 Images
were captured every 2 hours during the first 10 hours and at 24 hours
after the beginning of the experiment. Wounds were measured with
microscope software (LSM 5 Pascal software and Axiovert 200M mi-
croscope; Carl Zeiss Meditec, Oberkochen, Germany).
To study the effect that several antagonists against the MAPK and
RhoA/ROCK pathways have on the corneal epithelial migration rate in
the presence or absence of Ap4A or Ap3A (100 M), we placed U0126
100 M, or AG1478 (100 M), or inhibitors of the actin cytoskeleton
pathway (Y27632, 100 nM and ()-blebbistatin, 10 M) for 30 minutes
(after medium removal) in Locke medium. In the presence of the
inhibitors, Ap4A or Ap3A (100 M) was added to the culture, and the
cells were exposed for 2 minutes. After this incubation, the cells were
washed, and fresh MEM was added. The dinucleotide/antagonist dose
was added to the wound at time 0 and 6 hours, as previously described.
Images were captured every 2 hours during the first 10 hours and at 24
hours after the beginning of the experiment.
Between different images, the cells were kept in a CO2 incubator at
37°C in 5% CO2 and 95% humidity.
Western Blot Analysis
For Western blot analysis of the activation of ERK1/2 and RhoA/ROCK
pathways, SIRC confluent monolayers were wounded as described
earlier. In the presence or absence of Ap4A or Ap3A 100 M, the
antagonists suramin (for Ap4A) and RB-2 (for Ap3A) and the inhibitors
U0126 and Y27632 were assayed at 100 M and 100 nM, respectively,
by using the same protocol as previously described for the migration
assays.
After collection, the cells were lysed in 20 mM Tris (pH 7.5), 150
mM NaCl, Triton X-100 (containing 1 mM PMSF, 1 mM NaF, 1 mM
Na3VO4, 1 g/L pepstatin A, 2 g/L leupeptin, and 1 g/L apro-
tinin). After centrifugation at 15,000 rpm 20 minutes 4°C to remove
debris, the supernatants were collected. To separate cytoplasm from
the nuclear fraction, we suspended the cells in two volumes of buffer
A (MgCl2 1.5 mM, KCl 10 mM, and Tris [pH 7.9] 10 mM) containing 1
mM PMSF, 1 mM NaF, 1 mM Na3VO4, 1 g/L pepstatin A, 2 g/L
leupeptin, 1 g/L aprotinin, and 0.05% NP-40. After the mixture was
centrifuged at 2,500g, the supernatants containing the cytosolic solu-
ble fraction were collected. The pellet was resuspended in 1 volume of
buffer B (glycerol 20%, MgCl2 1.5 mM, KCl 10 mM, and Tris [pH 7.9]
20 mM) and 2:3 volume of buffer C (glycerol 20%, MgCl2 1.5 mM, KCl
1.2 M, and Tris [pH 7.9] 20 mM) containing 1 mM PMSF, 1 mM NaF, 1
mM Na3VO4, 1 g/L pepstatin A, 2 g/L leupeptin, and 1 g/L
aprotinin. After 45 minutes’ incubation on ice, the pellet was centri-
fuged at 20,000g, and the supernatants were collected. Protein con-
centration was determined by Bradford protein assay. Protein (45 g)
was subjected to SDS-PAGE (10% for ERK1/2, 7% for ROCK-I, and 12%
for pMLC2) and transferred to a nitrocellulose membrane. To block
nonspecific binding, we treated the membranes with PBS with 5%
skimmed milk and then incubated them overnight with primary anti-
bodies against pERK1/2, ROCK-I, and pMLC2 diluted 1:1000 in PBS/
Tween-20 0.05% containing 2% skimmed milk. The membranes were
then washed three times (10 minutes per wash) with PBS/Tween-20
0.05%, and further incubated with the goat anti-mouse IgG-HRP sec-
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ondary antibody diluted 1:2000. Proteins were visualized by enhanced
chemiluminescence detection according to the manufacturer’s proto-
col (GE Healthcare).
Blots were stripped (1 M Tris [pH 6.8], SDS 10%, and -mercapto-
ethanol), blocked and reprobed with ERK2 or MLC2 antibody diluted
1:1000, to check that all lanes were loaded with the same amount of
protein.
Intensities of the respective band were examined by densitometric
analysis (Kodak Gel Logic 2000 and Molecular Imaging Software; East-
man Kodak, Grupo Taper, Alcobendas, Madrid, Spain).
Immunocytochemistry for pERK and ROCK-I
In the presence of Ap4A or Ap3A 100 Mwith U0126 and Y27632 (100
M and 100 nM, respectively), we tested the intracellular distribution
of pERK and ROCK-I, to correlate results from Western Blot assays and
to look for a relationship between ERK1/2 and RhoA/ROCK pathways.
To localize the nucleus, we used the nucleic acid stain (PicoGreen;
Quant-it dsDNA BR Reagent, Quant-iT dsDNA Brand Range Assay Kit;
Invitrogen),38 because the PicoGreen dsDNA reagent is an ultrasensi-
tive fluorescent nucleic acid stain and can be used for immunostaining
with visible fluorescence in green.
SIRC cells were grown to 80% confluence on coverslips, and the
monolayers were wounded as previously described. These monolayers
were challenged for 30 minutes with U0126 (100 M) or Y27632 (100
nM), and in the presence of the inhibitor, the cells were incubated for
2 minutes with Ap4A or Ap3A 100 M. After this incubation, fresh MEM
was added, and the cells were incubated for 1 hour or 15 minutes to
obtain the maximum activation for pERK and ROCK-I, respectively.
After incubation, three washes in 10 PBS were performed, and the
cells were fixed for 15 minutes at room temperature with 4% parafor-
maldehyde in 0.15 M PBS. The cells were washed again with 10 PBS,
and were permeabilized with blocking solution (1 PBS, BSA 3%,
Triton X-100, and FBS 5%) for 1 hour at 37°C, to block nonspecific
binding. The cells were then washed with 1 PBS/BSA 3% and incu-
bated with primary mouse monoclonal anti-pERK or anti-ROCK-I (both
1:100) or 1 PBS/BSA 3% for negative controls at room temperature
for 1 hour. The cells were washed twice in 1 PBS/BSA 3% and
incubated with the secondary antibody goat anti-mouse IgG-TRICT
(1:200) for 1 hour at room temperature. At this time, the costaining
with 1:200 green nuclear stain was performed by adding the stain to
the secondary antibody solution. Finally, three washes in 1 PBS were
performed, and coverslips were applied to the slides with mounting
medium (Invitrogen). The cells were observed by confocal microscope
(Axiovert 200M; Carl Zeiss Meditec), equipped with a Pascal confocal
module (LSM 5; Carl Zeiss Meditec). All images were managed with the
accompanying Pascal software.
Analysis of Data
To model the nonlinear decrease in wound area during epithelial
healing, we used a modified version of a previously described constant-
velocity method.36 Briefly, migration rates were determined by linear
regression of the decrease in wound area during 10 hours of measure-
ments and were obtained by the slope of the regression line expressed
as the percentage of decrease in area per hour. The total time of wound
closure was calculated by extrapolation of the best fit of the regression
line during the healing phase to 100% closure of each wound tested.
Migration rates, expressed as the estimated migration rate (EMR)
and the estimated time for wound closure, presented as estimated
healing time (EHT) in treated and control wounds, were compared by
ANOVA test. Average values were expressed as the mean  SEM. The
levels of significance for the differences are indicated in each case in
the figure legends.
When we represent linear regression of the decrease in wound
area, data are expressed as a percentage of the initial wound width, to
normalize variability in wounding from well to well and experiment to
experiment according to the same strategy as described in other
studies.39,40 EMR variations are expressed as the percentage area de-
crease in area  hours1, and all data are related to the control (time 0
hours), to minimize the intrinsic values of the medium.
To quantify Western blot analysis of pERK, ROCK-I, and pMLC2, we
performed densitometry, and band intensities were relativized to ERK2
or MLC2. Variations in intensity were expressed as a percentage of the
control and expressed as the mean  SEM, because all data are related
to a control, to minimize the intrinsic levels that occur with the wound
closure.
Intracellular distribution of pERK1/2 and ROCK-I was determined
by densitometric quantification of pERK1/2 and ROCK-I signal inten-
sity in the nucleus and in the cytoplasm of several images (n  4). In
each case, the results were expressed as mean  SEM and represented
in arbitrary units.
RESULTS
Migration Assays
To correlate our wound healing results from primary corneal
epithelial23 cells with the establish cell line SIRC, we per-
formed a migration assay with Ap4A and Ap3A (100 M) in
SIRC monolayers. A comparison between the behavior of SIRC
cells and primary cultured corneal epithelial cells in migration
studies can be performed by comparing Tables 1 and 2. Values
in both systems are almost identical for the effects of Ap4A and
Ap3A. Therefore, all the experiments regarding the second-
messenger cascades were performed in the SIRC cell line.
Figure 1A, shows the effects of Ap4A and Ap3A on wound
healing. As can be seen, Ap4A significantly increased the EMR
(4.35%  0.11%) when compared with the control (3.28% 
0.27%). This change represents a concomitant decrease in
EHT, with closure of the wound occurring 8 hours earlier than
in the absence of any added substance. On the other hand,
Ap3A slowed the migration rate (2.98%  0.17%) when com-
pared with the control and increased EHT by 3 hours. In Figure
1B, a series of micrographs in which we can compare the
effects of Ap4A and Ap3A on epithelial cell migration is shown.
To understand the role that MAPK and actin cytoskeleton
pathways have on rabbit corneal epithelial cell migration trig-
gered by Ap4A or Ap3A, we tested several inhibitors of both
pathways. Wounded cells were preincubated for 30 minutes in
the presence of the indicated inhibitor, and then were incu-
bated for 2 minutes with the corresponding agonist, as de-
scribed in the Methods section.
In SIRC cells, the preincubation with U0126 and AG1478,
before Ap4A application, produced a delay in cell migration
(with a reduction in EMR). U0126 delayed EMR and increased
TABLE 1. EMRs and EHTs for Ap4A and Ap3A 100 M in Wound
Healing in the Presence of Antagonists in SIRC Cells
Compound EMR (%) EHT (h)
Control 3.28  0.27 8
Ap4A 100 M 4.35  0.11*** 0
U0126Ap4A 100 M 2.52  0.32*** 12
AG1478Ap4A 100 M 2.20  0.19*** 26
Y27632 100 nMAp4A 100 M 3.21  0.68** 6
()-Blebbistatin 10 MAp4A 100 M 2.51  1.0* 12
Ap3A 100 M 2.98  0.17*** 0
U0126Ap3A 100 M 3.35  0.42 4
AG1478Ap3A 100 M 2.71  0.31 8.5
Y27632 100 nMAp3A 100 M 3.69  0.61 6
()-Blebbistatin 10 MAp3A 100 M 1.51  0.35*** 10.5
Data are the mean  SEM of eight independent experiments. ,
delay induced by Ap4A or Ap3A 100 M compared with the control;,
acceleration compared with the same control data.
***P  0.0001, **P  0.01, *P   0.1 vs. Ap4A or Ap3A alone.
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EHT by 12 hours (P 0.0002), and AG1478 reduced EMR with
a delay in EHT of 26 hours, both statistically significant when
compared with Ap4A alone (Fig. 2A, Table 1). When we as-
sayed the inhibitors of actin cytoskeleton pathway in the pres-
ence of Ap4A, we observed that both Y27632 and ()-bleb-
bistatin produced a statistically significant delay in EMR with an
increased in EHT (6 hours for Y27632 and 12 hours for ()-
blebbistatin; Fig. 2B, Table 1).
In accordance with our previous work, Ap3A delayed EMR,
and the preincubation with U0126 in the presence of this
dinucleotide produced an acceleration in EMR with a decrease
in EHT of 3 hours when compared with Ap3A alone. The
preincubation with AG1478 produced a long delay in the
migration rate, increasing the EHT 8.5 hours (Fig. 2C, Table 1).
The preincubation with the different inhibitors for actin cy-
toskeleton, produced two different behaviors in the migration
rate: (1) Y27632 produced an increase in EMR with a decrease
in EHT of 6 hours when compared with Ap3A alone, and (2)
TABLE 2. EMRs and EHTs for Ap4A and Ap3A 100 M in Wound
Healing in the Presence of Antagonists in Primary Culture Cells
Compound EMR (%) EHT (h)
Control 4.20  0.15 5
Ap4A 100 M 6.25  0.33*** 0
U0126Ap4A 100 M 3.62  0.42*** 12
AG1478Ap4A 100 M 3.16  0.09*** 26
Y27632 100 nMAp4A 100 M 4.62  0.62** 6
()-Blebbistatin 10 MAp4A 100 M 3.62  1.2* 12
Ap3A 100 M 3.83  0.18*** 0
U0126Ap3A 100 M 4.31  0.47 4
AG1478Ap3A 100 M 3.48  0.22 8.5
Y27632 100 nMAp3A 100 M 4.75  0.51 6
()-Blebbistatin 10 MAp3A 100 M 1.94  0.31*** 10.5
Data are the mean  SEM of eight independent experiments. ,
delay induced by Ap4A and Ap3A 100 M compared with the control;
, acceleration compared with the same control values.
***P  0.0001, **P  0.01, *P  0.1 vs. Ap4A and Ap3A alone.
FIGURE 1. Effects of Ap4A and Ap4A
on SIRC cell migration. (A) The vari-
ation of the wounded area versus
time after the protocol. (B) A series
of micrographs allows comparison of
the migration process in control con-
ditions and after Ap4A and Ap3A, 100
M each, on cultured cell monolay-
ers. The images were obtained at 0,
6, and 10 hours in the absence (con-
trol) or presence of the dinucleotides.
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()-blebbistatin produced a statistically significant delay in
EMR with an increase in EHT of 10.5 hours (Fig. 2D, Table 1).
When we tested the four inhibitors alone, U0126 100 M,
AG1478, Y27632, and ()-blebbistatin delayed the migration
rate in a statistically significant manner: 1.9% 0.42%, 1.63%
0.41%, 3.12%  0.50%, and 1.99%  0.50%, respectively (con-
trol 3.28%  0.27%). Concomitantly, the estimated healing
time increased 11 hours for U0126, 13 hours for AG1478, 1
hour for Y27632, and 20 hours for ()-blebbistatin; Figs. 2E, 2F).
When migration assays were performed in primary culture
cells, similar results were obtained (Table 2).
Activation of MAPK and Actin
Cytoskeleton Pathways
To confirm the activation of the intracellular pathways previ-
ously studied in the migration assays, we analyzed pERK1/2
and ROCK-I by Western blot. These experiments were per-
formed on wounded SIRC monolayers after treatments with
Ap4A or Ap3A, with or without antagonists of P2Y receptors or
MAPK and RhoA/ROCK inhibitors, as described in the Methods
section.
When we studied the activation of pERK1/2 in wounded
epithelial cells in the presence of Ap4A or Ap3A, we observed
that Ap4A promoted a rapid (5 minutes) and sustained activa-
tion of pERK1/2, with a maximum of activation at 1 hour
(28.71%  1.48% above control). In the case of Ap3A, the
pERK1/2 activation also reached maximum activation at 1 hour
(13.03%  1.22% above control levels; results not shown).
ROCK-I was activated after incubation with Ap4A present-
ing a maximum of activation of 10.05%  0.90% 15 minutes
after the application of the dinucleotide. When we tested
ROCK-I activation in the presence of Ap3A in wounded mono-
layers, we observed a minimal increased 30 minutes after the
application of this dinucleotide (3.24%  0.92%; results not
shown).
After setting the conditions for ERK1/2 and ROCK-I, we
performed pERK1/2 and ROCK-I activation assays in the pres-
ence of Ap4A or Ap3A, with several antagonists of the puriner-
FIGURE 2. Effect of MAPK and cy-
toskeleton inhibitors on the rate of
migration of corneal cells. (A)
Change in EMR (EMR) when the
inhibitors U0126 and AG1478 were
tested with Ap4A, both at 100 M.
(B) Effect of Y27632 and ()-bleb-
bistatin on the Ap4A rate of migra-
tion. (C) Effect of U0126 and AG1478
on Ap3A-induced migration delay.
(D) Effect of Y27632 and ()-bleb-
bistatin on Ap3A-induced migration.
(E, F) Effect of the four inhibitors in
the absence of any dinucleotide.
***P  0.0001, **P  0.01, *P  0.1
vs. Ap4A or Ap3A alone.
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gic receptors MAPK and Rho/ROCK, according to the protocol
described in the Methods section.
When we studied the activation of ERK1/2 by Ap4A alone,
we observed a statistically significant increase in phosphoryla-
tion (128.71  1.48) when compared with the control in the
absence of any added dinucleotide (100%  1.0%). In the
presence of Ap4A, pretreatments with suramin, U0126, and
Y27632, produced statistically significant increases in pERK1/2
activation: 91.35%  1.18%, 74.97%  0.42%, and 107.29% 
1.33%, respectively (Fig. 3A). When we tested how these three
antagonists affected the activation of ROCK-I, when compared
with Ap4A alone (110.05 0.90%), we observed that the three
antagonists reduced ROCK-I activation in a statistically signifi-
cant manner, the values being 104.19%  2.89% for suramin,
93.11%  0.98% for U0126, and 85.56%  0.19% for Y27632
(Fig. 3B).
The same experiments were performed for Ap3A. This dinu-
cleotide alone produced a statistically significant increase in
pERK1/2 of 113.03%  1.22%, and pretreatments with RB-2
and U0126 produced a statistically significant reduction in
ERK1/2 phosphorylation of 84.41%  0.58% and 72.47% 
0.18%, respectively. When the compound Y27632 was tested,
FIGURE 3. pERK1/2, ROCK, and
pMLC2 activation in the presence of
Ap4A or Ap3A 100 M with antago-
nists. (A) Activation of pERK1/2 by
Ap4A 100 M in the presence of
suramin, U0126, and Y27632. (B) Ef-
fect of suramin, U0126, and Y27632
100 M on the activation of ROCK-I
after Ap4A treatment. (C) Activation
of pERK by Ap3A 100 M in the pres-
ence of RB-2, U0126, and Y27632.
(D) Activation of ROCK-I after prein-
cubation with RB-2, U0126, and
Y27632 in the presence of Ap3A 100
M. (E) Activation of ERK1/2 by
suramin, RB-2, U0126, and Y27632 in
the absence of any dinucleotide. (F)
Effect of the antagonists alone on the
activation of ROCK-I. (G) Effect of
Ap4A and Ap3A alone and in the pres-
ence of Y27632 in the activation of
pMLC2 (***P  0.0005, **P  0.01,
*P  0.1 vs. Ap4A or Ap3A alone.
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a statistically significant increase in pERK1/2 (122.63% 
0.39%) was observed (Fig. 3C). As presented in Figure 3D,
there was a reduction in ROCK-I activation after pretreatment
with RB-2 and U0126, the values being 95.97%  3.24% and
91.20%  0.78%, respectively, when compared with Ap3A
alone (103.24%  0.92%), with these differences being statis-
tically significant. The pretreatment with Y27632 produced an
increase in the activation of ROCK-I (113.35%  0.33%).
When we tested the activation of both ERK1/2 and ROCK-I
in the presence of the antagonists alone, we observed that
suramin, RB-2, U0126, and Y27632 produced a statistically
significant decrease in pERK1/2 phosphorylation (9.77% 
1.0% for suramin, 11.98%  1.47% for RB-2, 30.2%  0.16% for
U0126, and 7.69% 0.70% for Y27632; Fig. 3E). When ROCK-I
activation was analyzed, the four antagonists produced a sim-
ilar effect (11.14%  0.86% for Suramin, 10.27%  0.54% for
RB-2, 8.78%  1.08% for U0126, and 14.99%  1.28% for
Y27632; Fig. 3F).
Rho/ROCK pathway involvement was further confirmed
with the study of the activation of myosin light chain kinase 2
phosphorylation (pMLC2), since this protein is downstream of
Rho/ROCK in this canonical intracellular pathway. Therefore,
Figure 3G shows the phosphorylation of this protein after
treatments with Ap4A, Ap3A, Y27632, Ap4A/Y27632, and
Ap3A/Y27632. Ap4A produced a statistically significant in-
crease in pMLC2 of 109.16%  0.41%, compared with the
control, which was reversed with the preincubation with the
antagonist to ROCK-I Y27632 (87.34%  0.84%), whereas
there was no increase in pMLC2 activation with Ap3A (101.82%
 0.91%, Fig. 3G).
Immunocytochemistry for pERK and ROCK
There were unexpected actions of some of the MAPK inhibi-
tors, such as U0126 acting on the ROCK-I pathway and vice
versa (Y27632 on the pERK pathway). To explain such appar-
ently unpredictable results, we investigated whether both
pathways are connected. In this sense, we investigated the
cellular distribution of pERK1/2 after treatment with Ap4A and
Ap4A with Y27632. In the absence of any added compound
(control condition), pERK was mainly localized in the cyto-
plasm with no colocalization detected with the green nuclear
dye, which means that in control situations, pERK was not
translocated to the nucleus. pERK1/2 activation by Ap4A was
distributed in a uniform pattern, with a good colocalization
with the nuclear marker, which means that it was in part
translocated to the nucleus, as indicated in another study.41
When Ap4A and Y27632 were combined, we observed that
pERK1/2 staining was mainly located in the cytoplasm, with
less staining in the nucleus, as revealed by less colocalization
with the green nuclear marker (Fig. 4A). Figure 4B shows the
pERK signal quantification in the cytoplasm and in the nucleus
of control cells and cells treated with Ap4A and Ap4A/Y27632.
As we observed, the amount of pERK in the cytoplasm of Ap4A
was higher than in the cytoplasm of Ap4A/Y27632 cells
(1151.91  7.26 and 1046.78  9.97. respectively), and the
amount of pERK in the cytoplasm of control cells was the
lowest (861.64 13.31). The same occurred with the nucleus,
with the control having less signal for pERK (3095.42  7.19
for Ap4A, 1871.27  9.35 for Ap4A/Y27632, and 328.56 
7.15, P  0.0001), which is consistent with less colocalization
of the green dye and with less translocation of pERK to the
nucleus. All differences are statistically significant.
When we performed the immunocytochemical staining for
ROCK-I alone, after Ap4A, and after Ap4A with U0126 (Fig. 4C),
we observed that ROCK-I stained the whole cytoplasm of the
cells in all three cases, without colocalizing with the nuclear
staining in any of them. Ap4A-treated cells presented more
staining for ROCK-I than in any of the other assays. ROCK-I
staining for Ap4A in the presence of U0126 was less intense
than that for Ap4A alone. When we quantified the ROCK-I
signal in the cytoplasm and in the nucleus (Fig. 4D), we
observed that the signal in the cytoplasm of the Ap4A-chal-
lenged cells was more robust (1038.77  15.35) than in the
cytoplasm of Ap4A/U0126-treated cells (907.78  10.92), and
that in the control cells, the signal was intermediate (983.86 
6.17). The same occurred with the amount of ROCK-I in the
nucleus. In Ap4A/U0126-treated cells, signaling for ROCK-I was
less intense (860.81  10.01) than in the nucleus of Ap4A-
challenged cells (1219.52  11.96), with the nucleus showing
the least intense signal of all (738.70  3.52). Again, all differ-
ences are statistically significant (Fig. 4, legend).
In the case of Ap3A, we observed that pERK1/2 staining
after treatment with Ap3A and Ap3A with Y27632, was
distributed in a similar uniform pattern, with good colocal-
ization with nuclear staining, which shows that it translo-
cated to the nucleus (Fig. 4E). In control cells, pERK was
mainly localized in the cytoplasm with no colocalization
with the nuclear stain, which indicates that in control situ-
ations, pERK was not translocated to the nucleus (Fig. 4E).
Figure 4F revealed that the amount of pERK signal in Ap3A-
challenged cell cytoplasm was very similar to that in Ap3A/
Y27632-treated cells (988.11  9.43 and 1017.00  6.7,
respectively), whereas in control cell cytoplasm, the amount
was less (861.64  13.31). In the nucleus the presence of
p-ERK was significantly higher in both treatments
(2062.35  8.83 for Ap3A, and 1777.82  5.77 for Ap3A/
Y27632) than the nucleus staining in control cells (328.56 
7.15). All differences are statistically significant.
These results were confirmed by Western blot isolating the
cytosolic and nuclear fractions separately (Fig. 5). Compared
with the control experiment (100%  1.0%), cytosolic pERK
signal was significantly increased in cells treated with Ap4A
(120.25%  1.37%) and in those treated with Ap4A/Y27632
(108.72%  1.59%). Nuclear pERK signaling was also signifi-
cantly increased in relation to signaling in control nuclei
(114.90%  1.46% for Ap4A and 102.90%  1.70% for Ap4A/
Y27632; Fig. 5A). As observed, the treatment with Y27632
produced a strong, statistically significant decrease in pERK
translocation to the nucleus in relation to pERK signal in cells
treated with Ap4A alone.
In the case of ROCK-I, treatment with Ap4A produced a
statistically significant increase in signaling for ROCK-I in the
cytoplasm (108.63%  0.61%) compared with the control
experiment (100%  1.0%), whereas treatment with Ap4A/
U0126 did not affect ROCK-I activation (100.68%  0.54%).
The nuclear ROCK-I signaling, was not altered in Ap4A-treated
cells (101.24% 1.40%), whereas in Ap4A/U0126 treated cells,
nuclear ROCK signaling decreased significantly (88.77% 
1.18%) when compared with the level in the control (100% 
1.0%; Fig. 5B).
DISCUSSION
The present experimental work describes how Ap4A activates
two intracellular pathways, ERK and ROCK-I, to permit corneal
cell migration. One of the questions that arise from the migra-
tion assays is whether the rabbit immortalized cell line used
work behaves similarly to primary cells obtained from rabbit
cornea. The migration behavior after treatment with Ap4A and
Ap3A in the immortalized cell line and the primary cultures was
almost identical; therefore, we performed all the subsequent
experimental procedures on the immortalized cell line. The
results showed that the blockade of both pathways by means
of the corresponding inhibitors significantly reduced the ability
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FIGURE 4. Cellular distribution of pERK1/2 and ROCK after treatment with Ap4A and Ap3A in the presence and absence of various inhibitors. (A)
Immunocytochemical distribution of pERK signal in control cells and in the presence of Ap4A and Ap4A with Y27632, each 100 nM. Red: pERK1/2
signal; green: nuclear marker. (B) pERK signal quantification in the cytoplasm and nucleus of control cells and cells treated with Ap4A and
Ap4A/Y27632, 100 M and 100 nM, respectively. (C) Cellular distribution of ROCK-I in control cells and after Ap4A and Ap4A with U0126, each
100 M. Red: ROCK-I signal; green: nuclear marker. (D) Quantification of ROCK-I signal in the cytoplasm and in the nucleus of control, Ap4A, and
Ap4A/U0126, each 100 M. (E) Immunocytochemical distribution of pERK signal in control cells and after Ap3A and Ap3A with Y27632, 100 M
and 100 nM, respectively. Red: pERK1/2 signal; green: nuclear marker. (F) pERK signal quantification in the cytoplasm and in the nucleus of cells
treated with Ap3A and Ap3A/Y27632, 100 M and 100 nM, respectively. ***P 0.0001, **P 0.01, *P  0.1 vs. Ap3A or Ap4A alone. Magnification,
40.
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of Ap4A to increase the rate of healing. In the case of Ap3A,
since this compound delayed cell migration, a contrary effect
was observed in the assay of these compounds.
The actions of Ap4A and Ap3A are triggered after stimula-
tion of the P2Y2 and P2Y6 receptors, respectively, as previ-
ously described.23,42 This effect was confirmed by use of the
selective P2 receptor antagonists.
It is reasonable to think that the increase in the migration
rate induced by Ap4A via P2Y2 receptors is linked to the
activation of the RhoA/ROCK pathway. Indeed, it has been
demonstrated that this pathway is linked to the actin cytoskel-
eton–changing cellular contractility.30 This possibility has
been confirmed by using compounds that inhibiting this path-
way, such as Y27632 and ()-blebbistatin, which inhibit
ROCK-I and myosin light kinase phosphorylation, which sig-
nificantly abolishes the pro-migratory effect of Ap4A. The same
inhibition of cell migration can be obtained when the P2Y2
receptor stimulated by Ap4A is antagonized with suramin, not
only when studying cell migration23 but also when analyzing
ROCK-I phosphorylation (Fig. 3B). In a previous work, we have
demonstrated that migration in corneal wounds produced in
rabbit corneas is blocked by the PKC inhibitor staurosporine.22
This suggests that P2Y2 receptors can activate the classic PLC
and PKC activation pathway and that this would be connected
with RhoA/ROCK activation. In addition, the P2Y2 receptors
present in corneal epithelial cells can activate the MAP kinase
cascade, as was demonstrated in the present study. Indeed,
Ap4A also activated the p42/p44 pathway. In this case,
43 the
tyrphostin AG1479 or the MEK inhibitor U0126 avoided the
phosphorylation of ERK1/2. The involvement of this pathway
has been demonstrated for P2Y2 receptors
43–45 and suggests
the transactivation of P2Y2 receptors with tyrosine kinase re-
ceptors such as the EGF receptor.22,32
It is important to note that both pathways seem to be
activated simultaneously, and unexpectedly, the inhibitors of
one of the cascades could modify the activity of the other. For
example, Y27632 significantly reduced the phosphorylation of
ERK1/2 triggered by Ap4A. Also U0126 reduced the phosphor-
ylation of ROCK-I. Of note, when U0126 was assayed, migra-
tion was reduced below the control level; and also, when
ROCK-I was analyzed, it presented expression levels that were
below those of the control. This result suggests that the main
pathway responsible for cell migration in corneal epithelial
cells is the one in which RhoA/ROCK are involved. On the
other hand, we cannot exclude ERK1/2’s participation in the
migration process; however, it seems to be plausible that the
MAPK cascade is more involved in processes related to long-
term effects, since ERK1/2 was translocated to the nucleus
(Figs. 4, 5). Also, the relation between ERK and ROCK-I is so
close that Y27632 hindered the translocation of p-ERK1/2 to
the nucleus (Figs. 4, 5). The biochemical meaning of this
cross-talk to be elucidated, and different and contradictory
hypotheses have been described regarding the possible con-
nection between pERK1/2 and ROCK-I pathways.41,46–48 Nev-
ertheless, some ideas can be suggested. Corneal wound healing
is a process divided in three steps: a lag phase (up to 8 hours
after the wound happened), migration step (24–36 hours), and
proliferation step (more than 36 hours until days).49 The latter
implies the activation of some processes in which the translo-
cation of p-ERK to the nucleus may be compulsory. It has been
demonstrated that inhibition of ERK1/2 reduces the process of
DNA synthesis and arrests the mitotic process.50 Indeed, ERK
activation is necessary for G2/M transition, as indicated in
another study,51 and so it would not be strange to think that
the P2Y2 activation by Ap4A, which involves ERK1/2 activa-
tion, prepares epithelial cells for the mitotic step in the corneal
wound-healing process (Fig. 6). More experiments are needed
to confirm this hypothesis.
On the other hand, Ap3A delayed the rate of healing, pre-
sumably by activating a P2Y6 receptor as previously reported.
23
Ap3A action was reversed by the MEK inhibitor U0126 but was
unaffected by AG1479, suggesting a different intracellular
mechanism from the one of Ap4A. The effect of the RhoA/
ROCK cascade inhibitors was contradictory. On the one hand,
the ROCK-I inhibitor enhanced migration (slightly but statisti-
cally significant), and on the other hand, the MLK inhibitor
delayed the rate of healing even more. It would be expected
that this pathway, in the presence of the inhibitors of the
RhoA/ROCK cascade, would not change that the inhibition
would be even more robust. These contradictory aspects sug-
gest the participation of other mechanisms that are not well
understood. In this sense, the confirmation of this inconsistent
FIGURE 5. Western-blot analysis of the cellular distribution of
pERK1/2 and ROCK signal after treatment with Ap4A in the presence
and absence of various inhibitors. (A) pERK activation in the cytoplasm
of cells treated with Ap4A and Ap4AY27632 and in absence of any
added compound. (B) ROCK-I signal in the nuclear fraction of the
treated cells. ***P  0.0001, **P  0.01, *P  0.1 vs. Ap4A alone.
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behavior also appears when ROCK-I is investigated. Y27632
increased the phosphorylation of this protein, in a result that
was consistent with the migration studies. Again, other mech-
anisms controlling the behavior of ROCK-I may explain the
delay produced by Ap3A.
Finally, we conclude that Ap4A, via the activation of the
P2Y2 receptor, activates both the MAPK and the RhoA/ROCK
pathways, and both are necessary for the migration process,
with ERK also involved in other long-term processes.
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